BridgeBio Oncology Therapeutics, Inc. Logo

BridgeBio Oncology Therapeutics, Inc.

Clinical-stage biopharma developing inhibitors for genetically driven cancers.

BBOT | US

Overview

Corporate Details

ISIN(s):
KYG4444H1011
LEI:
Country:
United States of America
Address:
256 E. GRAND AVENUE, SUITE 104, 94080 SOUTH SAN FRANCISCO

Description

BridgeBio Oncology Therapeutics, Inc. (BBOT) is a clinical-stage biopharmaceutical company focused on precision oncology. The company develops a pipeline of novel, bioavailable small molecule inhibitors designed to treat patients with RAS-dependent cancers and other malignancies with clear genetic drivers. Its core strategy centers on inhibiting active RAS, aiming to create transformative medicines that advance beyond current therapeutic approaches. BBOT was launched to accelerate the development of its parent company's precision oncology portfolio.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2024-12-15
English
4.2 MB
2024-10-30
German
1.8 MB
2024-08-14
French
0.5 MB
2024-05-22
English
2.1 MB
2024-03-10
English
3.5 MB
2024-01-15
German
1.2 MB
2023-11-20
English
5.1 MB

Full Filing History Restricted

Access to specific historical documents or filtered results is limited in the Web UI. Request access to the complete dataset.

Automate Your Workflow. Get a real-time feed of all BridgeBio Oncology Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BridgeBio Oncology Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BridgeBio Oncology Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Bone Biologics Corp Logo
Develops a protein-based bone graft substitute for spinal fusion procedures.
United States of America
BBLG
Bonyf N.V. Logo
Develops medical devices for oral, dental, orthodontic, and dermatological care.
Belgium
MLBON
Boryung Corporation Logo
A healthcare company developing pharmaceuticals and investing in health sector innovation.
South Korea
003850
Bosnalijek d.d. Sarajevo Logo
Develops, manufactures, and exports a wide range of pharmaceutical products.
Bosnia and Herzegovina
BSNL
Boule Diagnostics Logo
Provider of hematology systems for decentralized human and veterinary markets.
Sweden
BOUL
Boundless Bio, Inc. Logo
Clinical-stage oncology company targeting ecDNA in oncogene amplified cancers.
United States of America
BOLD
BridgeBio Pharma, Inc. Logo
Develops transformative medicines for genetic diseases and cancers.
United States of America
BBIO
BRIGHT MINDS BIOSCIENCES INC. Logo
Develops selective serotonin agonists for neurological and psychiatric disorders.
United States of America
DRUG
A clinical-stage biopharma company developing cancer immunotherapies and cell therapies.
Japan
4594
BRISTOL MYERS SQUIBB CO Logo
A global biopharmaceutical company that discovers, develops, and commercializes medicines.
United States of America
BMY

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.